Coya Therapeutics, Inc. (COYA)Healthcare | Biotechnology | Houston, United States | NasdaqCM
4.59 USD
-0.27
(-5.556%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.57 -0.02 (-0.019%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:32 a.m. EDT
The investment case for Coya Therapeutics is currently bifurcated between a compelling long-term narrative and a precarious short-term reality. Fundamentally, the company is showing signs of life with a 49% revenue growth rate and a price trajectory that has surged nearly 95% over the last two years, driven by positive year-over-year performance. However, these gains are built on a foundation of significant losses, with negative operating margins of nearly 29% and no free cash flow. The balance sheet remains fragile, relying on capital raises like the recent $11.1 million private placement to fund operations, while the gross margin is negative, indicating severe cost inefficiencies in production or sales. While analysts maintain a 'strong buy' rating with a mean target of $15, this optimism appears disconnected from the current operational burn rate and the lack of commercialized revenue. The stock is trading at a premium valuation relative to its sales, which is typical for biotech but risky without a proven product pipeline. In the short term, the technical picture is mixed; the stock is hovering near its 50-day average but lacks the explosive momentum needed to justify a bullish entry given the low reliability of statistical forecasts. The options market reflects this uncertainty, with heavy put buying at the $2.50 level acting as a psychological floor, while call interest at $7.50 represents a distant dream scenario. Until the company demonstrates a path to profitability or a major clinical milestone that de-risks the pipeline, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.074136 |
| AutoTheta | 0.098964 |
| AutoETS | 0.107884 |
| MSTL | 0.117786 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 0.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.895 |
| Excess Kurtosis | -0.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.403 |
| Market Cap | 107,671,528 |
| Forward P/E | -2.44 |
| Profit Margins | -270.22% |
| Website | https://www.coyatherapeutics.com |
As of Aug. 22, 2026, 2:32 a.m. EDT: Speculators are positioning for a range-bound outcome rather than a directional breakout. Call open interest is heavily concentrated at the $7.50 strike, suggesting a speculative ceiling or a 'lottery ticket' bet on a massive rally, while the bulk of volume sits at-the-money. Conversely, put open interest is significantly heavier at the $2.50 strike, indicating a defined floor where investors believe the stock could fall. The implied volatility gap between the near-term ATM ($26%) and deep OTM/ITM strikes suggests traders expect a potential spike in price movement but are hedging against a drop to the lower end of the range.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.29601228 |
| Address1 | 5,850 San Felipe St. |
| Address2 | Suite 500 |
| All Time High | 10.69 |
| All Time Low | 3.21 |
| Ask | 5.9 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 100,030 |
| Average Daily Volume3 Month | 194,287 |
| Average Volume | 194,287 |
| Average Volume10Days | 100,030 |
| Bid | 3.48 |
| Bid Size | 2 |
| Book Value | 1.845 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.59 |
| Current Ratio | 13.397 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.82 |
| Day Low | 4.55 |
| Display Name | Coya Therapeutics |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -20,830,436 |
| Ebitda Margins | -2.59759 |
| Enterprise To Ebitda | -3.096 |
| Enterprise To Revenue | 8.042 |
| Enterprise Value | 64,490,524 |
| Eps Current Year | -1.36667 |
| Eps Forward | -1.88 |
| Eps Trailing Twelve Months | -1.01 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8724 |
| Fifty Day Average Change | -0.28239965 |
| Fifty Day Average Change Percent | -0.057959046 |
| Fifty Two Week Change Percent | -29.601229 |
| Fifty Two Week High | 7.75 |
| Fifty Two Week High Change | -3.1599998 |
| Fifty Two Week High Change Percent | -0.4077419 |
| Fifty Two Week Low | 3.71 |
| Fifty Two Week Low Change | 0.8800001 |
| Fifty Two Week Low Change Percent | 0.23719679 |
| Fifty Two Week Range | 3.71 - 7.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,672,324,200,000 |
| Float Shares | 17,285,620 |
| Forward Eps | -1.88 |
| Forward P E | -2.4414895 |
| Free Cashflow | -11,967,820 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | -0.27 |
| Fullday Change Percent | -5.55555 |
| Fullday Price | 4.5712 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.08682 |
| Gross Profits | -8,715,404 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1469 |
| Held Percent Institutions | 0.33234 |
| Implied Shares Outstanding | 23,457,849 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-12-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas. |
| Long Name | Coya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 107,671,528 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_700238507 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,669,624 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 113,770,567 |
| Number Of Analyst Opinions | 7 |
| Open | 4.82 |
| Operating Cashflow | -15,722,176 |
| Operating Margins | -28.904518 |
| Payout Ratio | 0.0 |
| Phone | 800 587 8170 |
| Post Market Change | -0.018800259 |
| Post Market Change Percent | -0.40959167 |
| Post Market Price | 4.5712 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 4.86 |
| Price Eps Current Year | -3.3585284 |
| Price Hint | 4 |
| Price To Book | 2.487805 |
| Price To Sales Trailing12 Months | 13.426809 |
| Profit Margins | -2.70224 |
| Quick Ratio | 12.294 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.27 |
| Regular Market Change Percent | -5.55555 |
| Regular Market Day High | 4.82 |
| Regular Market Day Low | 4.55 |
| Regular Market Day Range | 4.55 - 4.82 |
| Regular Market Open | 4.82 |
| Regular Market Previous Close | 4.86 |
| Regular Market Price | 4.59 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 152,927 |
| Return On Assets | -0.32271 |
| Return On Equity | -0.60541 |
| Revenue Growth | 0.49 |
| Revenue Per Share | 0.403 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,457,849 |
| Shares Percent Shares Out | 0.045100003 |
| Shares Short | 1,057,492 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,048,435 |
| Short Name | Coya Therapeutics, Inc. |
| Short Percent Of Float | 0.045500003 |
| Short Ratio | 5.55 |
| Source Interval | 15 |
| State | TX |
| Symbol | COYA |
| Target High Price | 18.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 15.21429 |
| Target Median Price | 15.5 |
| Total Cash | 43,181,000 |
| Total Cash Per Share | 1.841 |
| Total Debt | 0 |
| Total Revenue | 8,019,145 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.895475 |
| Two Hundred Day Average Change | -0.30547476 |
| Two Hundred Day Average Change Percent | -0.062399413 |
| Type Disp | Equity |
| Volume | 152,927 |
| Website | https://www.coyatherapeutics.com |
| Zip | 77,057 |